How Celgene Stock Is Breaking All the Rules

Celgene Corp. (NASDAQ: CELG ) has been one of the fastest-growing biotechs for several years running now, fueled mainly by its megablockbuster blood cancer drug Revlimid. The company's ability to continually expand Revlimid's label for new indications, such as newly-diagnosed multiple myeloma, most recently, has repeatedly driven earnings and revenue to exceed annual guidance:

Hey, check out all the research scientist jobs. Post your resume today!